ANI Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) on April 7, 2026, covering events occurring on April 1, 2026. The filing addresses a change in the Company's independent registered public accounting firm.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance and audit matters.
Material Changes
- Dismissal of Auditor: On April 1, 2026, the Company dismissed EisnerAmper LLP as its independent registered public accounting firm, effective immediately.
- Appointment of New Auditor: On April 1, 2026, the Audit Committee appointed Ernst & Young LLP (EY) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Audit History: EisnerAmper's reports for fiscal years 2024 and 2025 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements regarding accounting principles or reportable events during the tenure of EisnerAmper.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed beyond the standard transition of audit firms. The Company confirmed that no consultations occurred with EY regarding accounting matters prior to their appointment.
Key Facts for Investor Verification
- Verify the effective date of the auditor transition (April 1, 2026) and the specific fiscal year EY will audit (2026).
- Review Exhibit 16.1 (EisnerAmper's letter) to confirm the auditor's agreement with the Company's statements regarding the dismissal.
- Monitor upcoming filings for the first financial statements audited by EY to assess any potential changes in accounting treatment or disclosure.
- Confirm that no "reportable events" or disagreements existed during the prior auditor's tenure as stated in the filing.